Vera Therapeutics (VERA) Equity Ratio (2020 - 2026)

Vera Therapeutics has reported Equity Ratio for 7 years, with the latest figure at 0.8 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 8.34% year-over-year to 0.8; the trailing twelve-month figure through Mar 2026 stood at 0.8 (down 8.34% YoY), and the FY2025 full-year result was 0.82, down 6.53% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.8, down from 0.82 in the prior quarter.
• The five-year high for Equity Ratio was 0.88 in Q4 2024, with the low at 0.58 in Q4 2023.
• Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.8 in 2022.
• The largest YoY upside for Equity Ratio was 145.25% in 2022 against a maximum downside of 29.58% in 2022.
• Vera Therapeutics' Equity Ratio stood at 0.59 in 2022, then declined by 1.01% to 0.58 in 2023, then surged by 51.96% to 0.88 in 2024, then slipped by 6.53% to 0.82 in 2025, then declined by 2.32% to 0.8 in 2026.
• The last three Equity Ratio figures came in at 0.8 (Q1 2026), 0.82 (Q4 2025), and 0.77 (Q3 2025), per Business Quant data.